H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 106 Citations 44,977 445 World Ranking 2899 National Ranking 284

Overview

What is she best known for?

The fields of study she is best known for:

  • Internal medicine
  • Cancer
  • Gene

Jane F. Apperley mainly investigates Internal medicine, Immunology, Transplantation, Myeloid leukemia and Surgery. Jane F. Apperley has included themes like Gastroenterology and Oncology in her Internal medicine study. In general Immunology, her work in Dasatinib and Interleukin 3 is often linked to In patient linking many areas of study.

Her Transplantation research incorporates themes from Stem cell, Bone marrow and Multiple myeloma. Her Myeloid leukemia research is multidisciplinary, relying on both Young adult, Discontinuation, ABL and Pharmacology. Her study in Surgery is interdisciplinary in nature, drawing from both Chronic leukemia, Hematology and Pediatrics.

Her most cited work include:

  • CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION (1441 citations)
  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 (1271 citations)
  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet (1080 citations)

What are the main themes of her work throughout her whole career to date?

Internal medicine, Transplantation, Immunology, Oncology and Surgery are her primary areas of study. Her work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology. Her Transplantation study combines topics in areas such as Stem cell, Bone marrow and Multiple myeloma.

Her Oncology research is multidisciplinary, incorporating perspectives in Cumulative incidence and Chronic myeloid leukaemia. Her work deals with themes such as Chronic myelogenous leukemia, Tyrosine kinase and Tyrosine-kinase inhibitor, which intersect with Imatinib. Her research integrates issues of Leukemia, Myelogenous and ABL in her study of Myeloid leukemia.

She most often published in these fields:

  • Internal medicine (60.42%)
  • Transplantation (34.41%)
  • Immunology (29.37%)

What were the highlights of her more recent work (between 2016-2021)?

  • Internal medicine (60.42%)
  • Oncology (30.07%)
  • Myeloid leukemia (23.50%)

In recent papers she was focusing on the following fields of study:

Her primary areas of investigation include Internal medicine, Oncology, Myeloid leukemia, Transplantation and Cancer research. Her Oncology research is multidisciplinary, incorporating elements of Clinical trial, Chronic myeloid leukaemia, Complete remission, Mesenchymal stem cell and Multiple myeloma. Her studies deal with areas such as Gold standard, Chronic myelogenous leukemia, Leukemia and Fusion transcript as well as Myeloid leukemia.

Jane F. Apperley has included themes like Intensive care medicine, Retrospective cohort study and Hazard ratio in her Transplantation study. Her Cancer research research also works with subjects such as

  • Stem cell together with Immunology, Disease and Bone marrow,
  • Cell that intertwine with fields like Cancer stem cell. In her study, which falls under the umbrella issue of Dasatinib, Pregnancy is strongly linked to Imatinib mesylate.

Between 2016 and 2021, her most popular works were:

  • Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. (441 citations)
  • Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. (243 citations)
  • Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. (190 citations)

In her most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

Her primary areas of study are Internal medicine, Myeloid leukemia, Transplantation, Oncology and Immunology. The concepts of her Myeloid leukemia study are interwoven with issues in Gold standard, Leukemia, ABL and Tyrosine-kinase inhibitor. In Transplantation, she works on issues like Human leukocyte antigen, which are connected to Complication, Adoptive cell transfer, Cytokine and Odds ratio.

Within one scientific family, she focuses on topics pertaining to Bone marrow under Oncology, and may sometimes address concerns connected to Umbilical cord and Cell therapy. Her Immunology research includes themes of Hematopoietic stem cell transplantation and Stem cell. Her Nilotinib research focuses on Dasatinib and how it connects with Discontinuation and Imatinib mesylate.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Blood (2013)

2068 Citations

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

Joan BladÉ;Diana Samson;Donna Reece;Jane Apperley.
British Journal of Haematology (1998)

1935 Citations

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus.
Blood (2006)

1700 Citations

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser.
Journal of Clinical Oncology (2009)

1667 Citations

Defining the intensity of conditioning regimens: working definitions.

Andrea Bacigalupo;Karen Ballen;Doug Rizzo;Sergio Giralt.
Biology of Blood and Marrow Transplantation (2009)

1221 Citations

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

David Marin;Alexandra Bazeos;Francois Xavier Mahon;Lina Eliasson.
Journal of Clinical Oncology (2010)

941 Citations

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre.
The New England Journal of Medicine (2013)

919 Citations

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation

A. Gratwohl;J. Hermans;J. Goldman;W. Arcese.
The Lancet (1998)

828 Citations

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton.
Blood (2007)

786 Citations

Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia

Jane F Apperley.
Lancet Oncology (2007)

765 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Jane F. Apperley

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 357

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 345

Arnon Nagler

Arnon Nagler

Sheba Medical Center

Publications: 247

Andreas Hochhaus

Andreas Hochhaus

Friedrich Schiller University Jena

Publications: 216

Mohamad Mohty

Mohamad Mohty

Université Paris Cité

Publications: 200

Michele Baccarani

Michele Baccarani

University of Bologna

Publications: 191

Nicolaus Kröger

Nicolaus Kröger

Universität Hamburg

Publications: 181

Bipin N. Savani

Bipin N. Savani

Vanderbilt University Medical Center

Publications: 173

Giuseppe Saglio

Giuseppe Saglio

University of Turin

Publications: 164

Elias Jabbour

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Publications: 156

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 153

Myriam Labopin

Myriam Labopin

Université Paris Cité

Publications: 147

Sergio Giralt

Sergio Giralt

Memorial Sloan Kettering Cancer Center

Publications: 146

Richard E. Champlin

Richard E. Champlin

The University of Texas MD Anderson Cancer Center

Publications: 140

Hillard M. Lazarus

Hillard M. Lazarus

Case Western Reserve University

Publications: 140

Gérard Socié

Gérard Socié

Université Paris Cité

Publications: 130

Something went wrong. Please try again later.